Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00757783 |
Recruitment Status
:
Completed
First Posted
: September 23, 2008
Results First Posted
: September 10, 2010
Last Update Posted
: December 30, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV | Drug: ritonavir Drug: darunavir Drug: emtricitabine [FTC]/tenofovir [TDF] Drug: atazanavir | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 68 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multicenter, Open-label, Randomized Study to Assess the Metabolics, Efficacy, and Safety of Once-daily Darunavir Versus Atazanavir in HIV-infected Treatment-naive Adult Patients |
Study Start Date : | October 2008 |
Actual Primary Completion Date : | August 2009 |
Actual Study Completion Date : | July 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: darunavir
darunavir 800 mg tablet once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg tablet once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
|
Drug: ritonavir
100 mg capsule or tablet once daily for 48 weeks
Drug: darunavir
800 mg tablet once daily for 48 weeks
Drug: emtricitabine [FTC]/tenofovir [TDF]
200/300 mg tablet once daily for 48 weeks
|
Experimental: atazanavir
atazanavir 300 mg capsule once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
|
Drug: ritonavir
100 mg capsule or tablet once daily for 48 weeks
Drug: emtricitabine [FTC]/tenofovir [TDF]
200/300 mg once daily for 48 weeks
Drug: atazanavir
300 mg capsule once daily for 48 weeks
|
- Change From Baseline in Fasting Triglyceride (TG) Levels in the Lipid Evaluable (LE) Set at Week12 [ Time Frame: Baseline, Week 12 ]Observed values.
- Change From Baseline in Total Cholesterol (TC) Levels in the LE Set at Week 12 and 48 [ Time Frame: Baseline, Week 12 and 48 ]Observed Values
- Change From Baseline in Low Density Lipoprotein (LDL) Direct in the LE Set at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Observed Values
- Change From Baseline in High Density Lipoprotein (HDL) in the LE Set at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Observed Values
- Change From Baseline in Apolipoprotein A1 in the LE Set at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Observed Values
- Change From Baseline in Apolipoprotein B in the LE Set at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Observed Values
- Change From Baseline in TC/HDL Ratio in the LE Set at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Participants TC and HDL was analyzed at Baseline and Week 12 and 48. Change from Baseline at Week 12 and 48 was calculated as ratio using observed values.
- Change From Baseline in Glucose at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Participants glucose level was analyzed at Baseline and Week 12 and 48. Change from Baseline at Week 12 and 48 was reported.
- Change From Baseline in Insulin at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Participants insulin was analyzed at Baseline and Week 12 and 48 and change from Baseline at Week 12 and 48 were reported.
- Change From Baseline in Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Participants homeostasis model assessment-insulin resistance (HOMA-IR) were observed and change from Baseline were reported. HOMA-IR score was calculated as: (fasting plasma glucose*fasting serum insulin)/22.5. Low HOMA IR values indicate high insulin sensitivity and high HOMA IR values indicate low insulin sensitivity (insulin resistance).
- Antiviral Activity, Human Immunodeficiency Virus Type 1 (HIV-1) RNA. [ Time Frame: Week 12 and 48 ]Number of Participants with antiviral activity, human immunodeficiency virus Type 1 (HIV-1) RNA less than (<) 50 copies per milliliters (copies/mL) or < 400 copies/mL.
- Number of Participants With Antiviral Activity, HIV-1 RNA, Missing Values as Treatment Failure (M=F) [ Time Frame: Week 12 and 48 ]Number of participants with antiviral activity, HIV-1 RNA, missing values as treatment failure (Missing = Failure) were observed.
- Change From Baseline in HIV-1 RNA Viral Load at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]the HIV-1 RNA viral load was calculated using Log Base 10 transformed HIV-1 RNA observed values.
- Change From Baseline in CD4 Cell Count at Week 12 and 48, Observed Values. [ Time Frame: Baseline, Week 12 and 48 ]Participants' Cluster of Differentiation (CD) 4 Cell Count were at baseline and the change values at Week 12 and 48 were observed.
- Change From Baseline in Cluster of Differentiation (CD) 4 Cell Count at Week 12 and 48, Last Observation Carried Forward (LOCF). [ Time Frame: Baseline, Week 12 and 48 ]Participants' Cluster of Differentiation (CD) 4 Cell Count were observed at baseline and the change values at Week 12 and 48 was calculated using LOCF.
- Change From Baseline in Cluster of Differentiation (CD) 4 Percent at Week 12 and 48, Last Observation Carried Forward (LOCF). [ Time Frame: Baseline, Week 12 and 48 ]Participants' Cluster of Differentiation (CD) 4 percent were observed at baseline and the change values at Week 12 and 48 was calculated using LOCF.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV-1 RNA of 1000 copies/mL or more
- No previous treatment with antiretroviral drugs for more than 10 days
- Demonstrated sensitivity [Fold Change (FC) = lower Clinical Cut Off (CCO)] to tenofovir, darunavir and atazanavir
- Demonstrated sensitivity to emtricitabine defined as absence of M184V/I mutation
- Any CD4 (Cluster of Differentiation 4) cell count
Exclusion Criteria:
- Body mass index >30 kg/m2
- Laboratory parameters as follows: fasting glucose >110 mg/dL, Low-Density Lipoprotein (LDL) cholesterol >130 mg/dL, triglycerides >200 mg/dL
- Presence of any currently active AIDS-defining illness
- Treatment for primary HIV infection or postexposure prophylaxis for HIV
- Patients with acute or chronic hepatitis A, B or C infection

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00757783
United States, California | |
Los Angeles, California, United States | |
United States, Connecticut | |
Glastonbury, Connecticut, United States | |
United States, District of Columbia | |
Washington, District of Columbia, United States | |
United States, Florida | |
Fort Lauderdale, Florida, United States | |
Miami, Florida, United States | |
Orlando, Florida, United States | |
United States, Indiana | |
Indianapolis, Indiana, United States | |
United States, Massachusetts | |
Boston, Massachusetts, United States | |
United States, Minnesota | |
Minneapolis, Minnesota, United States | |
United States, Missouri | |
Saint Louis, Missouri, United States | |
United States, New Jersey | |
Hillsborough, New Jersey, United States | |
United States, New York | |
New York, New York, United States | |
United States, Ohio | |
Cincinnati, Ohio, United States | |
United States, Pennsylvania | |
Philadelphia, Pennsylvania, United States | |
United States, Texas | |
Dallas, Texas, United States |
Study Director: | Tibotec, Inc. Clinical Trial | Tibotec, Inc |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Tibotec, Inc |
ClinicalTrials.gov Identifier: | NCT00757783 History of Changes |
Other Study ID Numbers: |
CR015439 TMC114HIV4023 ( Other Identifier: Tibotec, Inc. ) |
First Posted: | September 23, 2008 Key Record Dates |
Results First Posted: | September 10, 2010 |
Last Update Posted: | December 30, 2015 |
Last Verified: | November 2015 |
Keywords provided by Tibotec, Inc:
HIV AIDS Immunodeficiency Virus, Human PREZISTA darunavir TMC114 |
Protease Inhibitor Truvada Atazanavir REYATAZ HIV Infections Treatment Naïve |
Additional relevant MeSH terms:
Ritonavir Darunavir Atazanavir Sulfate Tenofovir Emtricitabine HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors |